Delcath Systems Inc (DCTH)

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Delcath Systems Inc (DCTH) is listed on Nasdaq, where it has traded since October 19, 2000.

Listed On
Nasdaq
Listed Since
October 19, 2000
Employees
156
Market Cap
$541M

About Delcath Systems Inc

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 116 institutions reported holding DCTH, with 17.4 million shares worth $219.3 million in aggregate. The largest reported holder was Rosalind Advisors, with 3.3 million shares worth $41.6 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.

InstitutionSharesValueQuarter change
Rosalind Advisors3,300,389$42MUnchanged
BlackRock2,706,802$34MAdded 51.69%
Vanguard1,607,231$20MReduced 6.54%
Propel Bio Management871,460$11MReduced 11.05%
Geode Capital Management733,115$9MAdded 5.94%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is DCTH?

Delcath Systems Inc (DCTH) is listed on Nasdaq, where it has traded since October 19, 2000.

Who are the largest institutional holders of DCTH?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of DCTH were Rosalind Advisors, BlackRock and Vanguard.

How many institutions own DCTH?

116 institutions reported a position in DCTH for the quarter ended June 30, 2026, worth $219.3 million in total.

Did institutions buy or sell DCTH last quarter?

Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for DCTH.

Every reported institutional holder, plus insider and congressional trades in DCTH, on SentiSense.